Literature DB >> 15206078

Clinical trial experience with Functional Assessment of Cancer Therapy-Lung in conventional and targeted non-small cell lung cancer therapy.

Anne Heyes1.   

Abstract

Advanced non-small cell lung cancer is associated with a low rate of long-term survival and a range of painful and debilitating symptoms. Various self-report questionnaires have been developed to monitor non-small cell lung cancer-related symptoms and quality of life over the course of treatment. The Functional Assessment of Cancer Therapy-Lung questionnaire is a widely used and well-validated lung cancer-specific instrument. It has been used to assess quality of life in numerous lung cancer clinical trials investigating a variety of therapeutic agents, including chemotherapy, radiation therapy, and targeted therapy. The Functional Assessment of Cancer Therapy-Lung is predictive of both tumor response and patient survival, and has been found to be highly sensitive to changes in clinical indicators.

Entities:  

Mesh:

Year:  2004        PMID: 15206078     DOI: 10.1053/j.seminoncol.2004.04.009

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Cancer symptom response as an oncology clinical trial end point.

Authors:  Laura C Bouchard; Neil Aaronson; Kathleen Gondek; David Cella
Journal:  Expert Rev Qual Life Cancer Care       Date:  2018-06-07

Review 2.  An Update on the Quality of Life Measurements in Lung Cancer Patients Receiving Palliative Radiotherapy: A Literature Review.

Authors:  Dominic Chu; Jasmine Nguyen; Kaitlin Koo; Liang Zeng; Gillian Bedard; Henry Lam; Erin Wong; Marko Popovic; Edward Chow
Journal:  World J Oncol       Date:  2013-05-06

3.  Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain.

Authors:  Johanna Lister; Sanja Stanisic; Klaus Kaier; Christian Hagist; Dmitry Gultyaev; Stefan Walzer
Journal:  Clinicoecon Outcomes Res       Date:  2012-10-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.